Hydroxycarbamid Hexal

Hydroxycarbamide, the active ingredient in Hydroxycarbamid Hexal, is an antimetabolite presented as an oral formulation for oral use. It is employed in the management of sickle cell disease and several hematologic malignancies, including chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, and melanoma.

GNH USA supplies Hydroxycarbamid Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Hydroxycarbamid Hexal is used to treat diseases within the hematologic and oncologic spectrum. - Sickle cell disease: reduces frequency of vaso‑occlusive crises and improves hemoglobin levels. - Chronic myelogenous leukemia: helps control disease progression as part of targeted therapy regimens. - Polycythemia vera: lowers elevated red blood cell mass and decreases thrombotic risk. - Essential thrombocythemia: reduces platelet counts and mitigates clotting complications. - Melanoma: used as an adjunct in certain treatment protocols to inhibit tumor growth.

Hydroxycarbamid Hexal may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Fatigue: persistent tiredness. - Hair loss: temporary thinning or shedding. - Gastrointestinal discomfort: abdominal pain or diarrhea.

Serious or Rare Side Effects: - Bone marrow suppression: leading to severe anemia, neutropenia, or thrombocytopenia. - Liver toxicity: elevated transaminases or hepatitis. - Severe allergic reactions: rash, swelling, or anaphylaxis.

When prescribing Hydroxycarbamid Hexal, clinicians should observe several safety precautions. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess renal function: adjust use in patients with impaired kidney function. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use contraception: advise patients of reproductive potential to prevent fetal exposure. - Review concomitant myelosuppressive drugs: avoid additive bone‑marrow toxicity. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Hydroxycarbamid Hexal can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may cause profound bone‑marrow suppression. - Live vaccines: increased risk of infection due to immunosuppression. - Allopurinol: can enhance hydroxycarbamide toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of gastrointestinal irritation. - Antacids containing aluminum or magnesium: can reduce hydroxycarbamide absorption. - Penicillins and cephalosporins: may affect renal clearance. - Azathioprine: additive immunosuppressive effect.